TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.

Dear TrialNet family,

As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.

DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.

TrialNet Chair Kevan C. Herold, MD, reflects on advances in type 1 diabetes research and the need to continue testing promising treatments.

Dear TrialNet Family,

Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.

TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.

TrialNet is celebrating 20 years!

TrialNet Chair Dr. Kevan Herold celebrates 20 years of progress, looks forward to making T1D a disease of the past

Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.